Witnessing the stock’s movement on the chart, on N/A, BridgeBio Pharma Inc (NASDAQ: BBIO) set off with pace as it heaved 2.96% to $53.48, before settling in for the price of $51.94 at the close. Taking a more long-term approach, BBIO posted a 52-week range of $21.72-$54.60.
It was noted that the giant of the Healthcare sector posted annual sales growth of -3.04% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -3.04%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -22.37%. This publicly-traded company’s shares outstanding now amounts to $191.16 million, simultaneously with a float of $162.24 million. The organization now has a market capitalization sitting at $10.22 billion. At the time of writing, stock’s 50-day Moving Average stood at $49.86, while the 200-day Moving Average is $39.05.
BridgeBio Pharma Inc (BBIO) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. BridgeBio Pharma Inc’s current insider ownership accounts for 15.13%, in contrast to 89.29% institutional ownership. According to the most recent insider trade that took place on Sep 05 ’25, this organization’s Director sold 74,000 shares at the rate of 53.16, making the entire transaction reach 3,933,544 in total value, affecting insider ownership by 83,275. Preceding that transaction, on Sep 05 ’25, Company’s Chief Executive Officer sold 40,000 for 53.05, making the whole transaction’s value amount to 2,122,047. This particular insider is now the holder of 875,686 in total.
BridgeBio Pharma Inc (BBIO) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.66 per share during the current fiscal year.
BridgeBio Pharma Inc’s EPS decrease for this current 12-month fiscal period is -22.37% and is forecasted to reach -1.85 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 83.74% through the next 5 years, which can be compared against the -3.04% growth it accomplished over the previous five years trading on the market.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
Let’s observe the current performance indicators for BridgeBio Pharma Inc (BBIO). It’s Quick Ratio in the last reported quarter now stands at 5.08. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 43.36.
In the same vein, BBIO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -4.09, a figure that is expected to reach -0.88 in the next quarter, and analysts are predicting that it will be -1.85 at the market close of one year from today.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
Going through the that latest performance of [BridgeBio Pharma Inc, BBIO]. Its last 5-days volume of 2.01 million was inferior to the volume of 2.91 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 71.60% While, its Average True Range was 62.10.
Raw Stochastic average of BridgeBio Pharma Inc (BBIO) in the period of the previous 100 days is set at 95.09%, which indicates a major rise in contrast to 85.30% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 1.70 that was higher than 1.63 volatility it exhibited in the past 100-days period.
